Dostarlimab for the treatment of endometrium cancer and other solid tumors

被引：7
作者：
Rubio-Perez, J. [1 ]
Hernandez, R. [1 ]
Hernandez, T. [1 ,2 ]
Doger, B. [1 ,2 ]
Casado, V [1 ]
Moreno, V [1 ,2 ]
机构：
[1] Fdn Jimenez Diaz Univ Hosp, Med Oncol, Madrid, Spain
[2] Fdn Jimenez Diaz Univ Hosp, Early Phase Clin Trials Unit, START Madrid FJD, Madrid, Spain
来源：
DRUGS OF TODAY | 2021年 / 57卷 / 03期
关键词：
Dostarlimab; Anti-programmed cell death protein 1 (PD-1) therapy; Monoclonal antibodies; Cancer immunotherapy; Immune checkpoint inhibitors; Endometrial cancer; Solid tumors therapy; ANTI-PD-1; MONOCLONAL-ANTIBODY; ADVANCED MSI-H; PRELIMINARY SAFETY; CLINICAL-TRIAL; OPEN-LABEL; RECURRENT; PD-1; PEMBROLIZUMAB; MULTICENTER; NIVOLUMAB;
D O I：
10.1358/dot.2021.57.3.3233363
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lung cancer or melanoma. The preliminary results, particularly in endometrial cancer, show a high affinity against PD-1 with encouraging clinical activity. Here we summarize the development of this compound as well as the current preclinical and clinical data and potential future development.
引用
收藏
页码：187 / 197
页数：11
相关论文
共 46 条
  • [1] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
    Alsaab, Hashem O.
    Sau, Samaresh
    Alzhrani, Rami
    Tatiparti, Katyayani
    Bhise, Ketki
    Kashaw, Sushil K.
    Iyer, Arun K.
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [2] Andre T., 2020, J CLIN ONCO S, V38
  • [3] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
    Andre, Thierry
    Berton, Dominique
    Curigliano, Giuseppe
    Ellard, Susan
    Trigo Perez, Jose Manuel
    Arkenau, Hendrik-Tobias
    Abdeddaim, Cyril
    Moreno, Victor
    Guo, Wei
    Im, Ellie
    Starling, Naureen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
    Antill, Yoland Catherine
    Kok, Peey Sei
    Robledo, Kristy
    Barnes, Elizabeth
    Friedlander, Michael
    Baron-Hay, Sally E.
    Shannon, Catherine M.
    Coward, Jermaine
    Beale, Philip James
    Goss, Geraldine
    Meniawy, Tarek
    Yip, Sonia
    Smith, Deborah
    Spurdle, Amanda B.
    Parry, Michelle
    Andrews, John
    Kelly, Marzena
    Stockler, Martin R.
    Mileshkin, Linda R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    [J]. LANCET ONCOLOGY, 2017, 18 (11) : 1483 - 1492
  • [6] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [8] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [9] Molecular characterization of endometrial cancer and therapeutic implications
    Chang, Zenas
    Talukdar, Shobhana
    Mullany, Sally A.
    Winterhoff, Boris
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2019, 31 (01) : 24 - 30
  • [10] Davar D., 2018, J IMMUNOTHER CANCER, V6, p115O21, DOI 10.1186/s40425-018-0423-x
12345